Related Experiment Video
Updated: Nov 4, 2025
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
CARD11 is a novel target of miR-181b that is upregulated in chronic lymphocytic leukemia
Zhen Kou1, Min Mao1, Hong Liu1
1Department of Hematology, The People's Hospital of Xin jiang Uygur Autonomous Region, Urumqi, China.
Insights
MicroRNA-181b targets CARD11 in chronic lymphocytic leukemia (CLL). Upregulated CARD11 in CLL patients indicates poor prognosis, identifying it as a potential biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Chronic lymphocytic leukemia (CLL) is a heterogeneous hematologic malignancy.
- MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
- Identifying novel molecular targets in CLL is essential for improving patient outcomes.
Purpose of the Study:
- To identify and validate the molecular targets of miR-181b in chronic lymphocytic leukemia.
- To investigate the clinical significance of identified targets in CLL patient survival.
Main Methods:
- Bioinformatic analysis to predict miR-181b target genes.
- Validation of target gene expression in CLL patient samples and cell lines.
- In vitro experiments including luciferase assays and Western blotting.
- Kaplan-Meier survival analysis.
Main Results:
- CARD11 was identified as a direct target gene of miR-181b.
- An inverse correlation between miR-181b and CARD11 expression was observed in CLL patients.
- High CARD11 expression was significantly associated with poor survival in CLL patients.
Conclusions:
- CARD11 is a novel, upregulated target of miR-181b in chronic lymphocytic leukemia.
- CARD11 serves as a potential prognostic biomarker for predicting survival in CLL patients.
Abstract:
Aim: To investigate the targets of miR-181b in patients with chronic lymphocytic leukemia (CLL). Materials & methods: The bioinformatic softwares were used to indicate the key target genes associated with miR-181b, and the results were verified in CLL patient samples and 293T cells. Results:CARD11 is a potential target gene of miR-181b, an inverse relationship was revealed between the expression of CARD11 and miR-181b in 104 CLL patients, and it was confirmed in vitro with luciferase assays and western blotting. Kaplan-Meier analysis showed that CLL patients with high CARD11 expression demonstrated poor survival. Conclusion:CARD11 is a novel target of miR-181b that is upregulated, which could be a poor prognostic indicator for CLL patients.
